



21 January 2021

ASX ANNOUNCEMENT

ImpediMed Quarterly Results and Investor Conference Call

Brisbane, Australia – ImpediMed Limited (ASX:IPD) advises it will release its Appendix 4C Cash Flow Statement and Quarterly Results for the period ending 31 December 2020 on Thursday 28 January 2021.

Investors are invited to join a conference call with Managing Director and CEO, Richard Carreon, at 9.15am AEDT on Thursday 28 January 2021.

To pre-register please follow this link:

<https://s1.c-conf.com/diamondpass/10011853-tsm294.html>

You will receive a calendar notification with dial in details and a PIN for fast track access to the call.

Approved for release by the Managing Director and CEO, Mr Richard Carreon.

Contact Details

Investor relations Contact:

Mike Bassett, ImpediMed

T: +61 407 431 432

E: mbassett@impedimed.com

Media Contact:

Kyahn Williamson, WE Communications

T: +61 3 8866 1200

E: kwilliamson@we-worldwide.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health.

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure, lymphoedema, and protein calorie malnutrition sold in select markets globally.

For more information, visit www.impedimed.com.